Literature DB >> 9573094

Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants.

R Dagan1, J Eskola, C Leclerc, O Leroy.   

Abstract

The plethora of newly discovered vaccines implies that, in the future, many vaccines will have to be administered simultaneously to infants. We examined the potential interference with the immune response of several coadministered vaccines containing the same protein component, namely, tetanus toxoid (TT). Infants simultaneously receiving a tetravalent pneumococcal vaccine conjugated to TT (PncT) and a diphtheria-tetanus-pertussis-poliovirus-Haemophilus influenzae type b-tetanus conjugate vaccine showed significantly lower anti-H. influenzae type b polysaccharide (polyribosylribitol phosphate [PRP]) antibody concentrations than those receiving either a tetravalent pneumococcal vaccine conjugated to diphtheria toxoid or placebo. A dose range study showed that anti-PRP antibody concentrations were inversely related to the TT content of the PncT vaccines administered in infancy. Postimmunization antitetanus antibody concentrations were also affected adversely as the TT content of the coadministered vaccines was increased. This phenomenon, which we believe derives from interference by a common protein carrier, should be taken into account when the introduction of an immunization program including multiple conjugate vaccines is considered.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9573094      PMCID: PMC108168          DOI: 10.1128/IAI.66.5.2093-2098.1998

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  23 in total

1.  Influence of prevaccination immunity on the human B-lymphocyte response to a Haemophilus influenzae type b conjugate vaccine.

Authors:  T Barington; K Kristensen; J Henrichsen; C Heilmann
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

Review 2.  Polysaccharide-protein conjugate vaccines for the prevention of Haemophilus influenzae type b disease.

Authors:  G A Weinberg; D M Granoff
Journal:  J Pediatr       Date:  1988-10       Impact factor: 4.406

3.  Priming with diphtheria-tetanus-pertussis vaccine enhances the response to the Haemophilus influenzae type b tetanus conjugate vaccine in infancy.

Authors:  S Kurikka
Journal:  Vaccine       Date:  1996-09       Impact factor: 3.641

4.  A perspective on issues relating to future vaccines.

Authors:  B R Bloom
Journal:  Ann N Y Acad Sci       Date:  1995-05-31       Impact factor: 5.691

Review 5.  Potential alterations in immunogenicity by combining or simultaneously administering vaccine components.

Authors:  R A Insel
Journal:  Ann N Y Acad Sci       Date:  1995-05-31       Impact factor: 5.691

6.  Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid.

Authors:  R Dagan; M Muallem; R Melamed; O Leroy; P Yagupsky
Journal:  Pediatr Infect Dis J       Date:  1997-11       Impact factor: 2.129

7.  Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory.

Authors:  H Ahman; H Käyhty; H Lehtonen; O Leroy; J Froeschle; J Eskola
Journal:  Pediatr Infect Dis J       Date:  1998-03       Impact factor: 2.129

8.  T cell recognition of Tn-glycosylated peptide antigens.

Authors:  T Jensen; L Galli-Stampino; S Mouritsen; K Frische; S Peters; M Meldal; O Werdelin
Journal:  Eur J Immunol       Date:  1996-06       Impact factor: 5.532

9.  Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines.

Authors:  C C Peeters; A M Tenbergen-Meekes; J T Poolman; M Beurret; B J Zegers; G T Rijkers
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

10.  Non-epitope-specific suppression of the antibody response to Haemophilus influenzae type b conjugate vaccines by preimmunization with vaccine components.

Authors:  T Barington; M Skettrup; L Juul; C Heilmann
Journal:  Infect Immun       Date:  1993-02       Impact factor: 3.441

View more
  45 in total

1.  Meningococcal group C conjugate vaccines.

Authors:  J Maclennan
Journal:  Arch Dis Child       Date:  2001-05       Impact factor: 3.791

2.  Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines.

Authors:  C Gravekamp; D L Kasper; L C Paoletti; L C Madoff
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  Safety and efficacy of combination vaccines.

Authors:  David Elliman; Helen Bedford
Journal:  BMJ       Date:  2003-05-10

4.  Haemophilus influenzae type b vaccine--booster campaign.

Authors:  Paul T Heath; Mary E Ramsay
Journal:  BMJ       Date:  2003-05-31

Review 5.  Conjugate vaccines.

Authors:  A Finn; P Heath
Journal:  Arch Dis Child       Date:  2005-07       Impact factor: 3.791

6.  Combined conjugate vaccines: enhanced immunogenicity with the N19 polyepitope as a carrier protein.

Authors:  Karin Baraldo; Elena Mori; Antonella Bartoloni; Francesco Norelli; Guido Grandi; Rino Rappuoli; Oretta Finco; Giuseppe Del Giudice
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

7.  Evaluation of combinatorial vaccines against anthrax and plague in a murine model.

Authors:  Amanda B DuBois; Lucy C Freytag; John D Clements
Journal:  Vaccine       Date:  2007-04-20       Impact factor: 3.641

8.  Recombinant group B streptococcus Beta C protein and a variant with the deletion of its immunoglobulin A-binding site are protective mouse maternal vaccines and effective carriers in conjugate vaccines.

Authors:  Hsiao-Hui Yang; Lawrence C Madoff; Hilde-Kari Guttormsen; Yong-Dong Liu; Lawrence C Paoletti
Journal:  Infect Immun       Date:  2007-04-30       Impact factor: 3.441

9.  Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components.

Authors:  Ron Dagan; David Goldblatt; James R Maleckar; Mansour Yaïch; Juhani Eskola
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

Review 10.  Interactions of conjugate vaccines and co-administered vaccines.

Authors:  H Findlow; R Borrow
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.